US 8258116
Combination therapy for the treatment of HCV infection
granted A61KA61K31/497A61K31/7068
Quick answer
US patent 8258116 (Combination therapy for the treatment of HCV infection) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Sep 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/497, A61K31/7068, A61K45/06, A61P